A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients
with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational
medication for MS, it is not a new drug. Abatacept has been approved by the FDA to treat
rheumatoid arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)